Selank

Selank is a synthetic heptapeptide (7 amino acids) developed at the Russian Institute of Molecular Genetics. It is a stabilized analogue of the endogenous tetrapeptide tuftsin, combined with a proline-glycine-proline tripeptide that dramatically extends its plasma stability. Approved in Russia for the treatment of generalized anxiety disorder (GAD) and as a nootropic, selank is notable for its anxiolytic effects that occur without sedation, tolerance, or physical dependence — a meaningful distinction from benzodiazepines. It also demonstrates clear nootropic properties, improving working memory, learning capacity, and stress resilience.

Selank's primary mechanism involves modulation of the GABAergic system — it enhances the activity of GABA-A receptors, explaining its anxiolytic effects, though through a different binding site than benzodiazepines, which is why it does not cause sedation or dependence. It also significantly increases BDNF (brain-derived neurotrophic factor) expression, promoting neuroplasticity, long-term potentiation, and memory consolidation. Selank upregulates enkephalin metabolism (increasing endogenous opioid peptide levels) and modulates the expression of interleukins including IL-6, providing anti-inflammatory effects in the CNS. It also influences serotonin, dopamine, and norepinephrine signaling — its broad neurochemical action profile accounts for its combined anxiolytic and cognitive-enhancing effects. Critically, it appears to normalize an overactive HPA stress response without blunting baseline cortisol.

Selank was developed at the Institute of Molecular Genetics (Moscow) and approved in Russia as a registered pharmaceutical for generalized anxiety disorder. Phase II and III clinical trials in Russia documented anxiolytic effects comparable to benzodiazepines without sedation, tolerance, or dependence — validated by double-blind placebo-controlled designs. Independent Russian clinical studies showed improvements in attention, memory, and verbal fluency in healthy volunteers and patients with mild cognitive impairment. Immunomodulatory studies documented modulation of IL-6 and other cytokines. BDNF upregulation has been confirmed in both animal and cell culture studies. Western research interest has grown since 2010, though no Western RCTs have been completed as of 2024.

Anxiety Research Protocol: Selank 500 mcg intranasally twice daily (morning and afternoon) for 14 days, with a 7-day break before repeating. Nootropic Performance Protocol: Selank 500–750 mcg intranasally before cognitively demanding tasks. Combined Cognitive Stack: Selank 500 mcg + Semax 200–300 mcg daily (different mechanisms, complementary effects on BDNF and neuropeptide modulation).

Selank has an exceptionally clean safety profile, validated through decades of Russian clinical and preclinical research. It does not cause sedation, cognitive impairment, motor incoordination, or the rebound anxiety seen with benzodiazepines. No dependence, withdrawal syndrome, or tolerance has been documented even with extended use. Mild nasal irritation with intranasal administration is the most commonly reported effect. Occasional mild fatigue or a subtle dream-like focus (the initial effect) is reported. No serious adverse events have been published in clinical literature. It does not interact with the cytochrome P450 enzyme system, minimizing drug interactions.

Store lyophilized selank powder or prepared nasal solution at 2–8°C, protected from light. The nasal solution (commercially prepared in Russia) is typically sold ready-to-use in amber dropper bottles at 0.15% concentration and is stable for the duration of the product shelf life when refrigerated. Reconstituted peptide for injection should be used within 14 days when refrigerated. Selank is relatively stable compared to many other peptides but degrades with repeated heat exposure.